Research uncovers Down's Syndrome link to rare leukemia

People with Down Syndrome (DS) have traditionally been recognized as having an increased risk of developing leukemia, specifically either acute megakaryoblastic leukemia (AMKL) or acute lymphoblastic leukemia (ALL). Until now, no one could say why but researchers from Northwestern University think they may have the answer to at least the increased risk of AMKL.

In Down Syndrome, a person has an extra chromosome: instead of having 2 copies of chromosome 21, they have three. Researchers hypothesezid that the increased risk of AMKL must exist somewhere on that extra chromosome, and they believe that they have found it in the increased expression of the protein templated by the chromosome 21 gene DYRK1A, which causes AMKL to develop in mice models of Down Syndrome.

Researchers were able to inhibit the activity of the DYRK1A gene in the lab, preventing the development of AMKL cells lines. Thus an inhibitors of DYRK1A activity could be a potentially very effective therapeutic response to DS patients with AMKL.

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap